Questions: Hemostasis: Platelet Aggregation, Coagulation, and Fibrinolysis

Question 1

A patient's blood work shows a prolonged PT (prothrombin time) but a normal aPTT (activated partial thromboplastin time). Which component is most likely deficient?

• A. The intrinsic pathway, since PT measures intrinsic pathway function
• B. Factor VII (extrinsic pathway), since PT measures the time to clot via tissue factor and is the only test affected by Factor VII deficiency
• C. The common pathway, since both PT and aPTT would be prolonged if the common pathway were deficient
• D. Primary hemostasis, since PT reflects platelet plug formation

Answer: (B)

PT (prothrombin time) assesses the extrinsic pathway initiated by tissue factor. The test bypasses the intrinsic pathway by adding exogenous tissue factor, so an isolated PT prolongation points to a defect in Factor VII (the only factor unique to the extrinsic pathway before the common pathway). Since aPTT (which assesses the intrinsic pathway) is normal, the common pathway is intact — confirming the defect is specifically in Factor VII. aPTT measures the intrinsic pathway (Factors XII, XI, IX, VIII). PT does not reflect platelet function.

Question 2

Why is fibrinolysis (clot dissolution by plasmin) considered an essential part of normal hemostasis rather than a pathological failure of clotting?

• A. Fibrinolysis removes the platelet plug while leaving the fibrin mesh intact for long-term wound repair
• B. Fibrinolysis dissolves the fibrin clot once tissue repair is underway, restoring vascular patency and preventing pathological thrombosis from occluding the vessel
• C. Fibrinolysis converts fibrin back to fibrinogen, which is then recycled for future clot formation
• D. Fibrinolysis activates protein C, which inhibits further thrombin production and limits clot size

Answer: (B)

Fibrinolysis is not a failure of hemostasis — it is the planned third phase. Tissue plasminogen activator (tPA) converts plasminogen (embedded in the clot) to plasmin, which cleaves fibrin into D-dimers and degradation products, dissolving the clot after tissue repair. Without fibrinolysis, clots would persist indefinitely and progressively occlude vessels — exactly what happens in pathological thrombosis. The balance between procoagulant forces and fibrinolysis keeps clotting localized and temporary. Elevated D-dimers in the blood are a clinical marker of active fibrinolysis.

Question 3

Thrombin is the central enzyme of the coagulation cascade because it both converts fibrinogen to fibrin and amplifies the cascade by activating additional clotting factors.

• T. True
• F. False

Answer: True

Thrombin (Factor IIa) is the pivotal enzyme of secondary hemostasis. It cleaves soluble fibrinogen into fibrin monomers that spontaneously polymerize, and activates Factor XIII to crosslink the fibrin polymer into a covalently stabilized mesh. Crucially, thrombin also amplifies the cascade: it activates Factors V and VIII (cofactors that dramatically accelerate Factor X activation and the prothrombinase complex). This positive feedback means that once a small amount of thrombin forms, the cascade amplifies rapidly. Thrombin also activates platelets, linking the coagulation cascade back to primary hemostasis.

Question 4

The intrinsic and extrinsic coagulation pathways operate largely independently and converge primarily at the final step of fibrin formation.

• T. True
• F. False

Answer: False

The intrinsic and extrinsic pathways converge at Factor X activation — the beginning of the common pathway — not at fibrin formation. Both pathways activate Factor X (which, with Factor V, forms the prothrombinase complex), which then converts prothrombin to thrombin, and thrombin converts fibrinogen to fibrin. Furthermore, the pathways interact during amplification: the extrinsic pathway's TF-VIIa complex can activate Factor IX (an intrinsic pathway component). The clean separation into 'intrinsic' and 'extrinsic' is a laboratory classification (based on which factors are measured by PT vs. aPTT) not a reflection of fully independent in vivo pathways.

Question 5

Explain why the balance between procoagulant factors and anticoagulant inhibitors (antithrombin III, protein C, protein S) is essential for normal vascular function rather than simply a safety valve.

Model answer: Coagulation is a powerful amplifying cascade that, once triggered, could rapidly thrombose the entire circulatory system if unchecked. Inhibitors (antithrombin III inactivates thrombin and Factors Xa and IXa; protein C/S inactivate Factors Va and VIIIa; TFPI inhibits the extrinsic pathway) continuously limit clot formation to the site of injury. Without this balance, thrombin generated at a small wound site could propagate throughout the circulation, causing disseminated intravascular coagulation (DIC). The inhibitors ensure clotting is local, proportional, and temporary — matching clot size to injury size and dissolving it once repair is complete.

The clinical significance is profound: when this balance tips, both bleeding and thrombosis result depending on direction. Factor V Leiden (resistant to protein C degradation) shifts the balance toward thrombosis. Deficiencies in antithrombin III or protein C cause hypercoagulable states. Conversely, hemophilia (Factor VIII or IX deficiency) reduces procoagulant capacity, causing bleeding. Normal hemostasis requires the system to be poised between these extremes — a dynamic balance maintained continuously, not just triggered by injury.